0001104659-22-087924.txt : 20220809 0001104659-22-087924.hdr.sgml : 20220809 20220809162551 ACCESSION NUMBER: 0001104659-22-087924 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220809 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220809 DATE AS OF CHANGE: 20220809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vaccitech plc CENTRAL INDEX KEY: 0001828185 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40367 FILM NUMBER: 221148726 BUSINESS ADDRESS: STREET 1: UNIT 6-10, ZEUS BUILDING STREET 2: RUTHERFORD AVENUE, HARWELL CITY: DIDCOT STATE: X0 ZIP: OX11 0DF BUSINESS PHONE: 44 (0) 1865 818808 MAIL ADDRESS: STREET 1: UNIT 6-10, ZEUS BUILDING STREET 2: RUTHERFORD AVENUE, HARWELL CITY: DIDCOT STATE: X0 ZIP: OX11 0DF FORMER COMPANY: FORMER CONFORMED NAME: Vaccitech Ltd DATE OF NAME CHANGE: 20201014 8-K 1 tm2222823d1_8k.htm FORM 8-K
0001828185 false GA 0001828185 2022-08-09 2022-08-09 0001828185 dei:FormerAddressMember 2022-08-09 2022-08-09 0001828185 VACC:AmericanDepositarySharesMember 2022-08-09 2022-08-09 0001828185 us-gaap:CommonStockMember 2022-08-09 2022-08-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 9, 2022

 

 

 

VACCITECH PLC

(Exact name of registrant as specified in its charter)

 

 

 

England and Wales 001-40367 Not Applicable

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

 

Vaccitech plc

Unit 6-10, Zeus Building Rutherford Avenue,

Harwell, Didcot, OX11 0DF

United Kingdom

(Address of principal executive offices, including zip code)

 

+44 (0) 1865 818 808

(Registrant’s telephone number, including area code)

 

The Schrödinger Building

Heatley Road

The Oxford Science Park

Oxford OX4 4GE

United Kingdom

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trade Symbol(s) Name of each exchange on which
registered
American Depositary Shares VACC The Nasdaq Global Market
Ordinary shares, nominal value £0.000025 per share*    

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

*American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) ordinary share. Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8.

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 9, 2022, Vaccitech plc announced its financial results for the quarter ended June 30, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

   
99.1 Press Release dated August 9, 2022.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

 

  Vaccitech plc
     
Date: August 9, 2022 By:

/s/ William Enright

    William Enright
    Chief Executive Officer

 

 

 

 EX-99.1 2 tm2222823d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

 

Oxford, United Kingdom, August 9, 2022 - Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Company’s recent corporate developments. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity, and cancer.

 

“The highlight of another productive quarter was interim data from our ongoing Phase 1b/2a clinical trial of VTP-300 in patients with chronic hepatitis B,” said Bill Enright, Vaccitech’s CEO. “We saw not only a robust T Cell response, but also sustained HBsAg reductions with a single treatment - interim data points that, to our knowledge, have not been observed together in clinical trials of other immunotherapeutics in this indication. This quarter we have recognized further royalty and milestone payments related to the sales of Vaxzevria®, AstraZeneca’s COVID-19 vaccine, which have contributed significant non-dilutive capital to support the company’s clinical and preclinical programs going forward.”

 

Second Quarter 2022 and Recent Corporate Developments

 

License revenue:

 

·On April 6, 2022, the Company announced that it had been notified of the commencement of royalty payments related to commercial sales of Vaxzevria®. The Company’s share of milestone and royalty payments received by Oxford University Innovation, or OUI, from AstraZeneca in the second quarter of 2022 amounted to $17.1 million, relating to commercial sales of Vaxzevria® during the first quarter of 2022.

 

Clinical developments:

 

·On April 29, 2022, the Company received scientific advice from the EMA defining a licensure pathway for its MERS vaccine candidate, VTP-500.

 

·In May, the Company completed enrollment for a Phase 1b/2a clinical trial, HBV002, to evaluate the safety and immunogenicity of VTP-300 with or without an anti-PD-1 therapy in patients with chronic Hepatitis B (HBV) infection whose infection has been suppressed with oral antiviral medication.

 

·In June, Arbutus Biopharma Corporation (Arbutus) and the Company dosed the first patient in a randomized, multi-center, blinded Phase 2a clinical trial to evaluate the safety, antiviral activity, and immunogenicity of the combination of Arbutus’ RNAi therapy, AB-729, with the Company’s immunotherapy, VTP-300, plus standard of care for the treatment of patients with virologically suppressed chronic HBV infection.

 

·In June, at the 2022 EASL International Liver Congress™, the Company presented data showing that VTP-300, both as monotherapy and in combination with a single low-dose of nivolumab at the time of the booster dose, induced sustained reductions of HBV surface antigen (HBsAg) in some patients, and a robust T cell response, of which CD8+ T cells were predominant, against all encoded antigens in patients with chronic HBV infection.

 

 

 

·In July, the Company enrolled the 60th patient into the Company’s Phase 1b/2 clinical trial of VTP-200, HPV001, to evaluate a potential treatment for persistent high-risk HPV infection.

 

Pre-clinical development:

 

·In April, the Company launched a program for the treatment of HPV-associated cancers and moved forward with a second immunotherapeutic program designed to induce regulatory T cells in patients with celiac disease, both utilizing the SNAPvax™ platform.

 

Upcoming Milestones

 

·In the fourth quarter of 2022, the Company expects to report additional data from the ongoing Phase 1b/2a clinical trial of VTP-300 in patients with chronic HBV infection.

 

·In the fourth quarter of 2022, the Company expects to initiate dosing of HBV003, a Phase 2b clinical trial of VTP-300 in patients with chronic HBV infection.

 

·In the fourth quarter of 2022, the Company expects to initiate dosing in a Phase 1/2 clinical trial of VTP-850 in patients with prostate cancer.

 

·In the first quarter of 2023, the Company intends to conduct an interim efficacy review of HPV001, a Phase 1b/2 clinical trial of VTP-200, a potential treatment for low grade HPV-related cervical lesions.

 

·In 2023, the Company expects to submit Investigational New Drug (IND) applications for its two lead SNAPvax candidates, VTP-1000 for the treatment of celiac disease and VTP-1100 for the treatment of HPV-associated cancers.

 

Second Quarter 2022 Financial Highlights:

 

·Cash position: As of June 30, 2022, cash and cash equivalents were $192.3 million, compared to $214.1 million as of December 31, 2021. The decrease in cash was primarily due to $15.0 million of net cash used in operating activities, $3.1 million of net cash used in investing activities, and an effect of $3.5 million from exchange rate movements on cash and cash equivalents.

 

·Revenues: Revenues were $17.1 million in the second quarter of 2022 compared to $15.0 million in the first quarter of 2022. Revenues comprised the Company’s share of milestone and royalty payments received by OUI from AstraZeneca related to commercial sales of Vaxzevria®.

 

·Research and development expenses: Research and development expenses were $9.7 million in the second quarter of 2022 compared to $10.7 million in the first quarter of 2022. The decrease in R&D expenses from the previous quarter was primarily due to lower R&D personnel-related costs and decreased spending on the development of VTP-200 and VTP-850.

 

 

 

·General and administrative expenses: General and administrative expenses were a gain of $6.4 million (after including a foreign exchange gain of $15.2 million) in the second quarter of 2022, compared to an expense of $3.9 million (after including a foreign exchange gain of $5.3 million) in the previous quarter. Excluding the foreign exchange gain, G&A expenses were $8.8 million in the second quarter of 2022, which were mainly attributable to personnel expenses of $4.3 million, including the share-based payment charge of $2.1 million, insurance costs of $1.6 million, and legal and professional fees of $1.0 million. Excluding the foreign exchange gain, G&A expenses for the previous quarter were $9.2 million and were mainly attributable to personnel expenses of $4.3 million, including the share-based payment charge of $3.1 million, insurance costs of $1.7 million, and legal and professional fees of $1.3 million.

 

·Net Income: For the second quarter of 2022, the Company generated a net income attributable to its shareholders of $15.7 million, or $0.41 per fully diluted share and $0.42 per basic share, compared to a net income attributable to shareholders of $2.6 million, or $0.068 per fully diluted share and $0.070 per basic share, for the previous quarter.

 

About Vaccitech

 

Vaccitech plc (“the Company”) is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment of chronic infectious diseases, cancer, autoimmunity, and other diseases where the T cell arm of the immune system is believed to play an important role. The company’s proprietary platforms include modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other viral vectors including the well-validated Modified vaccinia Ankara (MVA), and synthetic nano-particle technologies (SNAPvax™ and Syntholytic™). The combination of different technologies in a mix and match approach (heterologous prime-boost) consistently generates significantly higher magnitudes of T cells compared with other technologies and approaches. The Company has a broad pipeline of both clinical and preclinical stage therapeutic programs to treat solid tumors, chronic viral infections as well as additional prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine, Vaxzevria®, with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through OUI. Vaccitech is entitled to receive a share of all milestone and royalty income received by OUI from AstraZeneca related to Vaxzevria®.

 

Forward Looking Statements

 

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by use of the words “may,” “will,” “could,” “if,” “forward,” “expect,” “intend,” “believe,” “estimate,” “potential,” “on track,” and similar expressions, although not all forward-looking statements contain these identifying words. These forward looking statements include express or implied statements regarding the Company’s future expectations, plans and prospects, and include, without limitation, statements regarding the timing and advancement of the Company’s programs, including the clinical trials of VTP-200, VTP-300, andVTP-850, statements regarding the timing for the potential IND applications for the Company’s two lead SNAPvax candidates, VTP1000 and VTP 1100, statements regarding the updated interim analysis from the HBV002 study, and statements regarding the Company’s capital . Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to: the success, cost and timing of the Company’s product development activities and planned and ongoing clinical trials, the Company’s ability to execute on its strategy, regulatory developments, the Company’s ability to fund its operations, global economic uncertainty and the impact that the current ongoing COVID-19 pandemic will have on the Company’s clinical trials, preclinical studies and access to capital and other risks identified in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2021, its Quarterly Report on Form 10-Q for the second quarter of 2022 and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

 

 

 

VACCITECH PLC 

CONDENSED Consolidated Balance SheetS

(In THOUSANDS, except Number of shares and per share AMOUNTS) 

(unaudited)

 

  

June 30,
2022

   December 31,
2021		 
ASSETS          
Current assets:          
Cash and cash equivalents  $192,327   $214,054 
Accounts receivable   -    20 
Accounts receivable - related parties   17,048    - 
Research and development incentives receivable   5,217    6,229 
Prepaid expenses and other current assets   11,699    6,462 
Total current assets   226,291    226,765 
Goodwill   12,630    12,630 
Property and equipment, net   7,044    1,829 
Intangible assets, net   29,850    31,430 
Right of use assets, net   8,339    7,257 
Other assets   902    804 
Total assets  $285,056   $280,715 
           
LIABILITIES AND SHARESHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $4,475   $2,419 
Accrued expenses and other current liabilities   7,256    7,875 
Deferred revenue   136    182 
Current portion of lease liability   299    523 
Debt   -    159 
Total current liabilities   12,166    11,158 
Lease liability – non current   8,314    6,540 
Contingent consideration   2,727    2,371 
Deferred tax liability, net   6,306    8,084 
Other non-current liabilities   776    - 
Total liabilities  $30,289   $28,153 
Commitments and contingencies          
Shareholders’ equity:          
Ordinary shares, £0.000025 nominal value; 37,216,162 shares authorized, issued and outstanding (December 31, 2021: authorized, issued and outstanding: 37,188,730)   1    1 
Deferred A shares, £1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2021: authorized, issued and outstanding: 63,443)   86    86 
Deferred B shares, £0.01 nominal value; 570,987 shares authorized, issued and outstanding (December 31, 2021: authorized, issued and outstanding: 570,987)   8    8 
Deferred C shares, £0.000007 nominal value, 27,828,231 shares authorized, issued and outstanding (December 31, 2021: authorized, issued and outstanding: 27,828,231)   0 1   0 1
Additional paid-in capital   375,835    369,103 
Accumulated deficit   (90,296)   (108,585)
Accumulated other comprehensive loss – foreign currency translation adjustments   (31,233)   (8,488)
Total shareholders’ equity attributable to Vaccitech plc shareholders’   254,401    252,125 
Noncontrolling interest   366    437 
Total shareholders’ equity  $254,767   $252,562 
Total liabilities and shareholders’ equity  $285,056   $280,715 

 

1 indicates amount less than thousand

 

 

 

 

VACCITECH PLC 

CONDENSED Consolidated StatementS of Operations and Comprehensive Loss 

(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS) 

(UNAUDITED)

 

   Three months ended   Six months ended 
   June 30, 2022   June 30, 2021   June 30, 2022   June 30, 2021 
License revenue (1)  $17,063   $16   $32,072   $32 
Service revenue   -    -    -    21 
Research grants and contracts   -    19    9    197 
Total revenue   17,063    35    32,081    250 
Operating expenses                    
Research and development   9,720    4,509    20,421    9,119 
General and administrative   (6,445)   12,371    (2,782)   14,148 
  Total operating expenses   3,275    16,880    17,639    23,267 
Income/(Loss) from operations   13,788    (16,845)   14,442    (23,017)
Other income (expense):                    
Change in fair value of derivatives embedded in convertible loan notes   -    -    -    5,994 
Change in fair value of contingent consideration   (626)   -    (626)   - 
Unrealized exchange gain on convertible loan notes   -    -    -    209 
Loss on extinguishment of convertible loan notes   -    -    -    (13,789)
Interest income   669    -    752    2 
Interest expense   66    -    (8)   (2,650)
Research and development incentives   826    875    1,874    1,830 
Other   51    (3)   51    (3)
  Total other (expense) income   986    872    2,043    (8,407)
Tax benefit /(expense)   915    (12)   1,778    53 
Net Income/(loss)   15,689    (15,985)   18,263    (31,371)
Net loss attributable to noncontrolling interest   4    58    26    176 
Net income/(loss) attributable to Vaccitech plc shareholders   15,693    (15,927)   18,289    (31,195)
                     
Weighted-average ordinary shares outstanding, basic   37,202,600    24,897,665    37,196,843    16,523,961 
Weighted-average ordinary shares outstanding, diluted   38,174,426    24,897,665    38,260,579    16,523,961 
Net income (loss) per share attributable to ordinary shareholders, basic  $0.42   $(0.64)  $0.49   $(1.89)
Net income (loss) per share attributable to ordinary shareholders, diluted  $0.41   $(0.64)  $0.48   $(1.89)
                     
Net Income/(loss)  $15,689   $(15,985)  $18,263   $(31,371)
Other comprehensive (loss)/income – foreign currency translation adjustments   (16,807)   86    (22,790)   (1,330)
Comprehensive loss   (1,118)   (15,899)   (4,527)   (32,701)
Comprehensive loss attributable to noncontrolling interest   34    55    71    169 
Comprehensive loss attributable to Vaccitech plc Shareholders  $(1,084)  $(15,844)  $(4,456)  $(32,532)

 

(1)Includes license revenue from related parties for the 3 and 6 month period ended June 30, 2022 of $17.1 million and $32.1 million, respectively.

 

 

 

 

Investors:

Vaccitech Investor Relations

ir@vaccitech.co.uk

 

Vaccitech Media Contacts:

 

Katja Stout, Scius Communications (EU) 

Direct: +44 (0) 7789435990 

Email: katja@sciuscommunications.com

 

Katie Larch / Robert Flamm, Ph.D., Burns McClellan, Inc. (U.S.)
Email: klarch@burnsmc.com / rflamm@burnsmc.com

 

 

 

 

 EX-101.SCH 3 vacc-20220809.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 vacc-20220809_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 vacc-20220809_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Addresses, Address Type [Axis] Former Address [Member] Class of Stock [Axis] American Depositary Shares[Member] Common Stock [Member] Entity Addresses [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] American Depositary Shares EX-101.PRE 6 vacc-20220809_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2222823d1_ex99-1img01.jpg GRAPHIC begin 644 tm2222823d1_ex99-1img01.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Aug. 09, 2022
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 09, 2022
Entity File Number 001-40367
Entity Registrant Name VACCITECH PLC
Entity Central Index Key 0001828185
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code X0
Entity Address, Address Line One Vaccitech plc
Entity Address, Address Line Two Unit 6-10
Entity Address, Address Line Three Zeus Building Rutherford Avenue
Entity Address, City or Town Harwell, Didcot
Entity Address, Country GB
Entity Address, Postal Zip Code OX11 0DF
City Area Code +44 (0)
Local Phone Number 1865 818 808
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
American Depositary Shares[Member]  
Document Information [Line Items]  
Title of 12(b) Security American Depositary Shares
Trading Symbol VACC
Security Exchange Name NASDAQ
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Ordinary shares, nominal value £0.000025 per share*
Former Address [Member]  
Document Information [Line Items]  
Entity Address, Address Line One The Schrödinger Building
Entity Address, Address Line Two Heatley Road
Entity Address, City or Town The Oxford Science Park
Entity Address, State or Province GA
Entity Address, Country GB
Entity Address, Postal Zip Code OX4 4GE
XML 9 tm2222823d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001828185 2022-08-09 2022-08-09 0001828185 dei:FormerAddressMember 2022-08-09 2022-08-09 0001828185 VACC:AmericanDepositarySharesMember 2022-08-09 2022-08-09 0001828185 us-gaap:CommonStockMember 2022-08-09 2022-08-09 iso4217:USD shares iso4217:USD shares 0001828185 false GA 8-K 2022-08-09 VACCITECH PLC X0 001-40367 Vaccitech plc Unit 6-10 Zeus Building Rutherford Avenue Harwell, Didcot OX11 0DF GB +44 (0) 1865 818 808 The Schrödinger Building Heatley Road The Oxford Science Park OX4 4GE GB false false false false American Depositary Shares VACC NASDAQ Ordinary shares, nominal value £0.000025 per share* true false 00-0000000 EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 4 26 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://vaccitech.co.uk/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2222823d1_8k.htm tm2222823d1_ex99-1.htm vacc-20220809.xsd vacc-20220809_def.xml vacc-20220809_lab.xml vacc-20220809_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2222823d1_8k.htm": { "axisCustom": 0, "axisStandard": 2, "contextCount": 4, "dts": { "definitionLink": { "local": [ "vacc-20220809_def.xml" ] }, "inline": { "local": [ "tm2222823d1_8k.htm" ] }, "labelLink": { "local": [ "vacc-20220809_lab.xml" ] }, "presentationLink": { "local": [ "vacc-20220809_pre.xml" ] }, "schema": { "local": [ "vacc-20220809.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 68, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 26, "memberCustom": 1, "memberStandard": 2, "nsprefix": "VACC", "nsuri": "http://vaccitech.co.uk/20220809", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2222823d1_8k.htm", "contextRef": "From2022-08-09to2022-08-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://vaccitech.co.uk/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2222823d1_8k.htm", "contextRef": "From2022-08-09to2022-08-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "VACC_AmericanDepositarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American Depositary Shares", "label": "American Depositary Shares[Member]" } } }, "localname": "AmericanDepositarySharesMember", "nsuri": "http://vaccitech.co.uk/20220809", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r14", "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesTable": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Container of address information for the entity", "label": "Entity Addresses [Table]" } } }, "localname": "EntityAddressesTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_FormerAddressMember": { "auth_ref": [ "r13", "r16" ], "lang": { "en-us": { "role": { "documentation": "Former address for entity", "label": "Former Address [Member]" } } }, "localname": "FormerAddressMember", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 10-Q", "Number": "249", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r14": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r15": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r16": { "Name": "Form 8-K", "Number": "249", "Publisher": "SEC", "Section": "308" }, "r17": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r18": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r19": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r20": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r21": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 17 0001104659-22-087924-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-087924-xbrl.zip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end